MedTrace Logo

MANP in African Americans With Hypertension

NCT04542681 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-09

No results posted yet for this study

Summary

Evaluate the cardiovascular properties of MANP in AA with Hypertension

Conditions

  • Hypertension, Resistant to Conventional Therapy

Interventions

DRUG

Placebo - 1st Cycle

Subjects will receive a single SQ injection of placebo/normal saline

DRUG

MANP - 1st Cycle

Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg

DRUG

MANP - 2nd Cycle

Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.

Sponsors & Collaborators

Principal Investigators

  • Paul M McKie, M.D. · Mayo Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2022-12-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542681 on ClinicalTrials.gov